Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2015

01-07-2015 | Research Article

The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan

Authors: Sarah Hasan, Abdul Hameed, Saima Saleem, S. M. Shahid, Ghulam Haider, Abid Azhar

Published in: Tumor Biology | Issue 7/2015

Login to get access

Abstract

Gene deletions in GSTM1 and GSTT1 may result in tempering the activation and detoxification of several carcinogens and thereby may increase the risk of cancer pre-disposition. This study aims to investigate the clinical impact of glutathione-S-transferase GSTM1 and GSTT1 polymorphisms on squamous cell carcinoma of cervix (SCCA).The GSTM1 and GSTT1 polymorphisms were analyzed in cervical cancer patients and healthy controls. Touch down multiplex polymerase chain reaction (PCR) strategy was adopted for genotyping of GSTM1 and GSTT1 polymorphisms. The null genotype of GSTM1 exhibited a significantly higher percentage in patients with SCCA (74 %) than in the control group (34.0 %). However, no significant difference was observed in the null genotype of GSTT1 among SCC patients and healthy subjects, respectively. GSTM1 exhibited a significant association with increased risk of squamous cell carcinoma (p < 0.001). The odds ratio for the GSTM1 null genotype was also calculated (odds ratio 3.7484; 95 % confidence interval 1.6562-84834). This suggests that GSTM1 null genotype in cervical cell samples may be associated with more severe precancerous lesions of the cervix.
Literature
1.
Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.CrossRefPubMed
2.
Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36.CrossRefPubMed
3.
Raymond MS, Proper S. Squamous cell carcinoma: a review of etiology, pathogenesis, treatment, and variants. J Dermatol Nurs Assoc. 2010;2:16–8.
4.
Rebbeck TR. Molecular epidemiology of the human glutathione S transferase genotype GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomark Prev. 1997;6:733–43.
5.
Heagerty AH, Fitzgerald D, Smith A, Bowers B, Jones P, Fryer A, et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet. 1994;343:266–8.CrossRefPubMed
6.
Stewart VN, Vaughan TL, Burt RD, Chen C, Berwick M, Swanson GM. Glutathione S-transferase M1 and susceptibility to nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 1999;8:547–51.
7.
Setiawan VW, Zhang ZF, Yu GP, Li YL, Lu ML, Tsai CJ, et al. GSTT1 and GSTM1 null genotypes and risk of gastric cancer: a case control study in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2000;9:73–80.PubMed
8.
Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22:7369–75.CrossRefPubMed
9.
Tiwawech D, Srivatanakul P, Karalak A, Ishida T. Glutathione S-transferase M1 gene polymorphism in Thai nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2005;6:270–5.PubMed
10.
Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. Biochem J. 2001;360:1–16.CrossRefPubMedPubMedCentral
11.
Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1997;6:733–43.PubMed
12.
Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res. 2000;463:247–83.CrossRefPubMed
13.
Deng Z, Wei Y, Ma Y. Glutathione-S-transferase M1 genotype in patients with hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 2001;23:477–9.PubMed
14.
Economopoulos KP, Sergentanis TN, Vlahos NF. Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. Int J Gynecol Cancer. 2010;20:732–7.CrossRefPubMed
15.
Lee SJ, Cho SH, Park SK, Kim SW, Park MS, Choi HY, et al. Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett. 2002;177:173–9.CrossRefPubMed
16.
Sweeney C, Stewart VN, Stapleton PL, Eaton DL, Vaughan TL. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2003;12:527–33.PubMed
17.
de Aguiar ES, Giacomazzi J, Schmidt AV, Bock H, Saraiva-Pereira ML, Schuler-Faccini L, et al. GSTM1, GSTT1, and GSTP1 polymorphisms, breast cancer risk factors and mammographic density in women submitted to breast cancer screening. Rev Bras Epidemiol. 2012;15:246–55.CrossRefPubMed
18.
Suzen S, Halit SS, Gulçin G, Mehmet T, Ela C, Yalçin D, et al. The Role of GSTM1 and GSTT1 polymorphisms in head and neck cancer risk. Oncol Res. 2007;6:423–9.
19.
Wang D, Wang B, Zhai JX, Liu DW, Sun GG. Glutathione S-transferase M1 and T1 polymorphisms and cervical cancer risk: a meta-analysis. Neoplasma. 2011;58:352–9.CrossRefPubMed
20.
Hu ZH, Lin YW, Xu X, Chen H, Mao YQ, Wu J, et al. Genetic polymorphisms of glutathione S-transferase M1 and prostate cancer risk in Asians: a meta-analysis of 18 studies. Asian Pac J Cancer Prev. 2013;14:393–8.CrossRefPubMed
21.
Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory; 1987.
22.
Sambrook J, Russel DW. Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory; 2001.
23.
Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics. 1996;6:187–91.CrossRefPubMed
24.
25.
Miller MC, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett. 2001;120:269–80.CrossRefPubMed
26.
Goodman MT, McDuffie K, Hernandez B, Bertram CC, Wilkens LR, Guo C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol. 2001;81:263–9.CrossRefPubMed
27.
Mishra S, Singh RB, Dwivedi SP, Meester FD, Rybar R, Pella D, et al. Effect of nutraceuticals on genetic expressions. Open Nutra J. 2009;2:70–80.CrossRef
28.
Kanzok SM, Fechner A, Bauer H, et al. Substitution of the thioredoxin system for glutathione reductase in Drosophila melanogaster. Science. 2001;291:643–6.CrossRefPubMed
29.
Lee S, Kim JW, Roh JW, Choi JY, Lee KM, Yoo KY, et al. Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol Oncol. 2004;93:14–8.CrossRefPubMed
30.
Economopoulos KP, Choussein S, Vlahos NF, Sergentanis TN. GSTM1 polymorphism, GSTT1 polymorphism, and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2010;20:1576–80.CrossRefPubMed
31.
Abbas M, Srivastava K, Imran M, Banerjee M. Association of glutathione S-transferase (GSTM1, GSTT1 and GSTP1) polymorphisms and passive smoking in cervical cancer cases from North India. Int J Biomed Res. 2013;4:655–62.CrossRef
32.
Ueda M, Toji E, Nunobiki O, Sato N, Izuma S, Torii K, et al. Germline polymorphisms of glutathione-S-transferase GSTM1, GSTT1 and p53 codon 72 in cervical carcinogenesis. Hum Cell. 2010;23:119–25.CrossRefPubMed
33.
Srivastava R, Sharma R, Mishra S, Singh RB. Biochemical and molecular biological studies on oral cancer: an overview. Open Nutra J. 2011;4:180–8.CrossRef
Metadata
Title
The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan
Authors
Sarah Hasan
Abdul Hameed
Saima Saleem
S. M. Shahid
Ghulam Haider
Abid Azhar
Publication date
01-07-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3175-y

Other articles of this Issue 7/2015

Tumor Biology 7/2015 Go to the issue

Research Article

Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma

Research Article

miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B–cell lymphoma

Research Article

Association of microRNA 17–92 cluster host gene (MIR17HG) polymorphisms with breast cancer

Research Article

Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours

Research Article

Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer

Research Article

Immunohistochemically detected expression of Skp2, p27kip1, and p-p27 (Thr187) in patients with cholangiocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits